Linagliptin and telmisartan induced effects on renal and urinary exosomal miRNA expression in rats with 5/6
Denis Delić1, Franziska Wiech2, Richard Urquhart2
1Boehringer Ingelheim Pharma GmbH & Co. KG, Translational Medicine & Clinical Pharmacology, Biberach, Germany. denis.delic@boehringer-ingelheim.com.
Abstract:
Dipeptidyl peptidase 4 inhibitors and angiotensin II receptor blockers attenuate chronic kidney disease progression in experimental diabetic and non-diabetic nephropathy in a blood pressure and glucose independent manner, but the exact molecular mechanisms remain unclear. MicroRNAs (miRNAs) are short, non-coding RNA species that are important post-transcriptional regulators of gene expression and play an important role in the pathogenesis of nephropathy. miRNAs are present in urine in a remarkably stable form, packaged in extracellular vesicles. Here, we investigated linagliptin and telmisartan induced effects on renal and urinary exosomal miRNA expression in 5/6 nephrectomized rats. In the present study, renal miRNA profiling was conducted using the Nanostring nCounter technology and mRNA profiling using RNA sequencing from the following groups of rats: sham operated plus placebo; 5/6 nephrectomy plus placebo; 5/6 nephrectomy plus telmisartan; and 5/6 nephrectomy plus linagliptin. TaqMan Array miRNA Cards were used to evaluate which of the deregulated miRNAs in the kidney are present in urinary exosomes. In kidneys from 5/6 nephrectomized rats, the expression of 13 miRNAs was significantly increased (>1.5-fold, P < 0.05), whereas the expression of 7 miRNAs was significantly decreased (>1.5-fold, P < 0.05). Most of the deregulated miRNA species are implicated in endothelial-to-mesenchymal transition and inflammatory processes. Both telmisartan and linagliptin suppressed the induction of pro-fibrotic miRNAs, such as miR-199a-3p, and restored levels of anti-fibrotic miR-29c. In conclusion, the linagliptin and telmisartan-induced restorative effects on miR-29c expression were reflected in urinary exosomes, suggesting that miRNA profiling of urinary exosomes might be used as a biomarker for CKD progression and monitoring of treatment effects.
Insights
Dipeptidyl peptidase 4 inhibitors and angiotensin II receptor blockers impact kidney disease by altering microRNA (miRNA) expression. Urinary exosomal miRNA profiling may serve as a biomarker for chronic kidney disease (CKD) progression and treatment monitoring.
Area of Science:
- Nephrology
- Molecular Biology
- Genomics
Background:
- Dipeptidyl peptidase 4 (DPP-4) inhibitors and angiotensin II receptor blockers (ARBs) slow chronic kidney disease (CKD) progression through unclear mechanisms.
- MicroRNAs (miRNAs) are key regulators of gene expression involved in kidney disease pathogenesis.
- Urinary exosomal miRNAs are stable and potentially useful biomarkers for kidney conditions.
Purpose of the Study:
- To investigate the effects of linagliptin (a DPP-4 inhibitor) and telmisartan (an ARB) on renal and urinary exosomal miRNA expression in a rat model of CKD.
- To explore potential molecular mechanisms underlying the renoprotective effects of these drugs.
Main Methods:
- Renal miRNA and mRNA profiling using Nanostring nCounter and RNA sequencing in sham-operated and 5/6 nephrectomized rats treated with placebo, telmisartan, or linagliptin.
- TaqMan Array miRNA Cards were used to validate kidney miRNA changes in urinary exosomes.
- Analysis focused on miRNAs implicated in endothelial-to-mesenchymal transition and inflammation.
Main Results:
- 5/6 nephrectomy significantly altered the expression of 20 miRNAs in the kidney (13 increased, 7 decreased).
- Both linagliptin and telmisartan suppressed pro-fibrotic miRNAs (e.g., miR-199a-3p) and restored anti-fibrotic miR-29c levels.
- Changes in miR-29c expression in the kidney were mirrored in urinary exosomes.
Conclusions:
- Linagliptin and telmisartan modulate specific miRNA profiles in the kidney, impacting fibrotic and inflammatory pathways.
- Restorative effects on miR-29c are detectable in urinary exosomes.
- Urinary exosomal miRNA profiling shows promise as a non-invasive biomarker for CKD progression and therapeutic response.


